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Introduction: Recently, a whole-exome sequencing (WES) study showed that a rare variant rs145999145 composed
of p.Val232Met located in exon 7 of the phospholipase D3 (PLD3) gene confers a doubled risk for late-onset Alzheimer’s
disease (AD). Knockdown of PLD3 elevates the levels of extracellular amyloid-beta (Aβ), suggesting that PLD3 acts as a
negative regulator of Aβ precursor protein (APP) processing. However, the precise cellular location and distribution of
PLD3 in AD brains remain largely unknown.
Methods: By quantitative RT-PCR (qPCR), western blot, immunohistochemistry, and bioinformatics analysis, we studied
PLD3 expression patterns and levels in a series of AD and control brains, including amyotrophic lateral sclerosis,
Parkinson’s disease, multiple system atrophy, and non-neurological cases.
Results: The levels of PLD3 mRNA and protein expression were reduced modestly in AD brains, compared with those
in non-AD brains. In all brains, PLD3 was expressed constitutively in cortical neurons, hippocampal pyramidal and
granular neurons but not in glial cells. Notably, PLD3 immunoreactivity was accumulated on neuritic plaques in AD
brains. We identified the human granulin (GRN) gene encoding progranulin (PRGN) as one of most significant genes
coexpressed with PLD3 by bioinformatics database search. PLD3 was actually coexpressed and interacted with PGRN
both in cultured cells in vitro and in AD brains in vivo.
Conclusions: We identified an intense accumulation of PLD3 on neuritic plaques coexpressed with PGRN in AD brains,
suggesting that PLD3 plays a key role in the pathological processes of AD.Introduction
Alzheimer’s disease (AD) is characterized by the hallmark
pathology, comprised of widespread amyloid-beta (Aβ) de-
position, neurofibrillary tangle formation, and extensive
neurodegeneration in the brain. The complex interaction
between multiple genetic and environmental factors
causes AD pathology [1]. Previously, genome-wide as-
sociation studies identified more than 20 common vari-
ants with lower penetrance and smaller risk for late-onset
AD [2]. Recently, whole-exome sequencing studies dis-
covered rare functional variants located in Aβ precursor
protein (APP), triggering receptor expressed on myeloid
cells 2 (TREM2), and phospholipase D3 (PLD3) genes
that exhibit a much greater contribution to protection
or development of AD [3-5].* Correspondence: satoj@my-pharm.ac.jp
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unless otherwise stated.Phospholipase D (PLD), a phospholipid-modifying en-
zyme whose activation is triggered by growth factors,
hormones, and neurotransmitters, catalyzes the hydrolysis
of phosphatidylcholine to generate free choline and
phosphatidic acid, the latter of which is converted into
diacylglycerol by phosphatidic acid phosphatases [6,7].
Both phosphatidic acid and diacylglycerol, by acting as
a second messenger, play a key role in membrane traffick-
ing, cytoskeleton reorganization, receptor-mediated endo-
cytosis, exocytosis, cell growth, differentiation, migration,
and regulation of the cell cycle. PLD is directly acti-
vated by phosphatidylinositol 4,5-bisphosphate, ADP-
ribosylation factor, Rho family small GTPases, and protein
kinase C [6,7].
Accumulating evidence showed a significant crosstalk
between PLD, APP, and presenilin-1 with relevance to
amyloidogenesis in AD brains [8]. The biochemical activ-
ity of PLD is decreased in AD brains [9]. The Aβ25–35
fragment stimulates PLD activity in LA-N-2 humantd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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formayl-peptide receptor-like-1 (FPRL1) activates PLD in
cultured rat astrocytes and microglia [11]. The human
genome contained six distinct genes encoding PLD en-
zymes, designated as PLD1 to PLD6. Among them,
both PLD1 and PLD2 regulate neurite outgrowth [12].
PLD1 is translocated to the Golgi/trans-Golgi complex
by interacting with the cytoplasmic loop region of
presenilin-1, and thereby negatively regulates Aβ pro-
duction [13]. Furthermore, PLD1 promotes trafficking
and cell surface accumulation of presenilin-1 in an
APP-independent manner [14]. Overexpression of APP
elevates PLD2 activity in P19 mouse embryonic carcinoma
cells [15]. PLD2 is required for the synaptotoxic action of
Aβ oligomers [16]. Thus, nearly all studies have previously
focused on a role of PLD1 and PLD2 in AD pathology.
PLD3 is a poorly characterized member of the PLD
superfamily, expressed abundantly in the central nervous
system, predominantly located in endoplasmic reticulum
(ER) in a subpopulation of neurons in the mouse brain
[17,18]. PLD3 protein consists of a transmembrane do-
main and two PLD phosphodiesterase domains with
two copies of the catalytically essential HXKXXXXD/E
(HKD) motif, the hallmark characteristic of the PLD
family, although neither canonical activity nor substrate
for PLD3 has so far been identified [17,18]. A recent study
showed that a single nucleotide variant numbered
rs145999145 in exon 7 of the human PLD3 gene on
chromosome 19q13.2, comprised of p.Val232Met located
in the phosphodiesterase domain close to the HKD motif,
confers a doubled risk for development of late-onset AD
in a large case–control series [5]. PLD3 interacts with
APP in cultured cells, and overexpression of PLD3 re-
duces intracellular APP and extracellular Aβ42 and Aβ40,
whereas knockdown of PLD3 elevates the levels of extra-
cellular Aβ42 and Aβ40, suggesting that PLD3 acts as a
negative regulator of APP processing [5]. However, the
precise cellular location and distribution of PLD3 in AD
brains remain largely unknown.
To study the role of PLD3 in AD pathology, we char-
acterized PLD3 expression patterns and levels in a series
of AD and non-AD brains by quantitative reverse
transcription-polymerase chain reaction (qPCR), western
blot, immunohistochemistry, and bioinformatics analysis.
We found that the PLD3 mRNA and protein levels are
reduced modestly in AD brains. Regardless of reduced
levels of PLD3, it is accumulated on neuritic plaques




For immunohistochemical studies, serial sections of the
frontal cortex and the hippocampus were prepared fromautopsied brains of 10 sporadic AD patients, composed of
five men and five women with a mean age of 70 ± 8 years,
and 13 non-AD patients, composed of six men and seven
women with a mean age of 74 ± 8 years, as described
previously [19]. The non-AD group includes four normal
subjects who died of non-neurological causes, three pa-
tients with sporadic Parkinson’s disease, four patients with
sporadic amyotrophic lateral sclerosis, and two patients
with sporadic multiple system atrophy. The demographic
profile of the cases is summarized in Table 1. All AD
cases satisfied the Consortium to Establish a Registry
for Alzheimer’s Disease criteria for diagnosis of definite
AD [20]. They were categorized into stage C of amyloid
deposition and stage VI of neurofibrillary degeneration,
following the Braak staging system [21]. Additional cases
for which frozen brain samples were available were in-
cluded for biochemical and genetic studies (Table 1).
Autopsies were performed at the National Center Hospital,
National Center of Neurology and Psychiatry, Japan or
Kohnodai Hospital, National Center for Global Health
and Medicine, Japan. The comprehensive examination of
autopsied brains by three established neuropathologists
(KA, YS, TI) validated the pathological diagnosis. In all
cases, written informed consent was obtained. The Ethics
Committee of the National Center of Neurology and
Psychiatry for the Human Brain Research, the Ethics
Committee of the National Center for Global Health and
Medicine on the Research Use of Human Samples, and
the Human Research Ethics Committee of the Meiji
Pharmaceutical University approved the present study.
Immunohistochemistry
The brain tissues were fixed with 4% paraformaldehyde
and embedded in paraffin. Tissue sections were deparaf-
finized and heat treated in 10 mM citrate sodium buffer,
pH 6.0 by autoclaving them at 110°C for 15 minutes in
a temperature-controlled pressure chamber (Biocare
Medical, Concord, CA, USA). For Aβ immunolabeling,
tissue sections were exposed to formic acid at room
temperature for 5 minutes. They were incubated at
room temperature for 15 minutes with 3% hydrogen
peroxide-containing methanol to block the activity of
endogenous peroxidase. They were incubated with
phosphate-buffered saline containing 10% normal goat
serum at room temperature for 15 minutes to block
nonspecific staining. The tissue sections were then in-
cubated at 4°C overnight with a rabbit polyclonal anti-
PLD3 antibody raised against a peptide spanning amino
acid residues 93 to 218 of the human PLD3 protein at a
concentration of 0.067 μg/ml (HPA012800; Sigma, St
Louis, MO, USA). The specificity of HPA012800 was vali-
dated by western blot analysis of recombinant Flag-tagged
PLD3 protein expressed in HeLa cells (Additional file 1).
After washing with phosphate-buffered saline, the tissue
Table 1 Demographic profile of the cases examined in the present study











NC1 + + Acute myocardial infarction 1,130 1.4 A/II V/V G/G
NC2 + + Acute myocardial infarction 1,350 1.6 0/II V/V G/G
NC3 + + Lung cancer 1,060 3.9 A/II V/V G/G
NC4 + + Dissecting aortic aneurysm 1,400 4.8 A/I V/V G/G
AD1 + + Pneumonia 1,000 1.1 C/VI V/V G/G
AD2 + + Pneumonia 1,230 14 C/VI V/V G/G
AD3 + + Pneumonia 1,220 10.5 C/VI V/V G/G
AD4 + + Pneumonia 1,240 8.1 C/VI V/V G/G
AD5 ND + Lung cancer 1,090 4.5 C/VI V/V G/G
AD6 + + Pulmonary infarction 840 3 C/VI V/V G/G
AD7 ND + Respiratory failure by aspiration 1,200 3.8 B/IV V/V G/G
AD8 + ND Pneumonia 1,060 8 C/VI ND ND
AD9 + ND Pneumonia 970 NA C/VI ND ND
AD10 + ND Pneumonia 870 1 C/VI ND ND
AD11 + ND Lung cancer 1,125 14.5 C/VI ND ND
AD12 + ND Multiple organ failure 775 13 C/VI ND ND
PD1 ND + Pneumonia 1,330 9.5 B/IV V/V G/G
PD2 + + Pneumonia 1,130 2.5 B/II V/V G/G
PD3 + + Respiratory failure by aspiration 910 2.5 B/II V/V G/G
PD4 ND + Colon cancer 1,430 4 A/I V/V G/G
PD5 + ND Pneumonia 1,320 9.3 C/III ND ND
ALS1 + + Respiratory failure 1,480 10.5 0/0 V/V G/G
ALS2 + + Respiratory failure 1,090 1.3 0/I V/V G/G
ALS3 + + Respiratory failure 1,560 3 0/I V/V G/G
ALS4 + + Respiratory failure 1,320 10 0/II V/V G/G
ALS5 ND + Respiratory failure 1,360 2.5 B/I V/V G/G
ALS6 ND + Respiratory failure 1,600 13 B/I V/V G/G
MSA1 + ND Pneumonia, septicemia 1,040 1.5 0/I ND ND
MSA2 + ND Pneumonia 1,090 12 A/I ND ND
Demographic profile of the cases processed for immunohistochemistry (IHC), quantitative reverse transcription-polymerase chain reaction (qPCR), and western blot
(WB) is shown with the case number, the cause of death, brain weight, the postmortem interval, the Braak Staging (amyloid deposition/neurofibrillary degeneration),
p.Val232Met variant of rs145999145, and c.1326G > A variant of rs4819. AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; MSA, multiple system atrophy; NA,
information not available; NC, non-neurological causes; ND, not determined; PD, Parkinson’s disease.
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with a peroxidase-conjugated secondary antibody (Nichirei,
Tokyo, Japan), followed by incubation with diaminobenzi-
dine tetrahydrochloride substrate (Vector, Burlingame,
CA, USA). Finally, they were processed for a counterstain
with hematoxylin. To prepare negative controls, the tissue
sections were incubated with the primary antibody preab-
sorbed by recombinant PLD3 fragment spanning amino
acid residues 93 to 218 (homemade).
For double-labeling, the tissue sections were initially
stained with a mouse monoclonal anti-Aβ11-28 antibody
(1 μg/ml, 12B2; Immunobiological Laboratory, Gunma,
Japan), a mouse monoclonal anti-PHF-tau antibody(0.25 μg/ml, AT8; Thermo Scientific, Rockford, IL, USA),
a mouse monoclonal anti-progranulin antibody (3.3 μg/ml,
PG359-7; Adipogen, Liestal, Switzerland), a mouse mono-
clonal anti-GFAP antibody (prediluted, GA5; Nichirei), or a
mouse monoclonal anti-CD68 antibody (prediluted,
KP1; Dako, Tokyo, Japan). They were then incubated
with an alkaline phosphatase-conjugated secondary anti-
body (Nichirei), and colorized with a Warp Red chromo-
gen (Biocare Medical). After autoclaving the sections, they
were relabeled with the anti-PLD3 antibody HPA012800,
followed by incubation with a peroxidase-conjugated sec-
ondary antibody (Nichirei), and colorized with diamino-
benzidine tetrahydrochloride substrate (Vector).
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Total cellular RNA was extracted from human neural cell
lines and tissues using TRIZOL (Invitrogen, Carlsbad, CA,
USA). RNA treated with DNase I was processed for cDNA
synthesis using oligo(dT)20 primers and SuperScript II re-
verse transcriptase (Invitrogen). cDNA was then amplified
by PCR using HotStar Taq DNA polymerase (Qiagen,
Valencia, CA, USA) on a PC815 thermal cycler (Astec,
Fukuoka, Japan) at 95°C for 1 minute for denaturation,
at 62°C for 40 seconds for annealing, and 72°C for 50 sec-
onds for extension for indicated cycles. PCR cocktails
were prepared individually by mixing with the following
sense and antisense primer sets: 5′-aagcctactgccttctgttggg
ac-3′ and 5′-caggcctggctttggctatgacat-3′ for a 153 base
pair product of the human PLD1 gene [NCBI:NM_
002662]; 5′-actgagggcagtgccctttgagat-3′ and 5′-tggcagg
agctgtgcttctccttt-3′ for a 209 base pair product of the
human PLD2 gene [NCBI:NM_002663]; 5′-tatcccccagc
cttgagggaagat-3′ and 5′-gagatgcaagtcgccgtattccca-3′ for
a 223 base pair product of the human PLD3 gene
[NCBI:NM_012268]; 5′-ggacgtgaaagtcttcatcgtgcc-3′ and
5′-cgtgctgctgaagtaatcctccga-3′ for a 142 base pair product
of the human PLD4 gene [NCBI:NM_138790]; 5′-aagcag
agtgcctcaaacctggtc-3′ and 5’tggtgcttgtgctggagataggca-3′
for a 239 base pair product of the human PLD5 gene
[NCBI:NM_152666]; 5’atctctgcctgttcgccttctcca-3′ and
5′-cttgtgatgcatgtagcctgggtc-3′ for a 191 base pair prod-
uct of the human PLD6 gene [NCBI:NM_178836]; and
5′-ccatgttcgtcatgggtgtgaacca-3′ and 5′-gccagtagaggc
agggatgatgttc-3′ for a 251 base pair product of the
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) gene
[NCBI:NM_002046], serving as a positive control.
For qPCR, cDNA prepared from frozen human brain tis-
sues and a reference RNA of the human frontal cortex
(AM6810; Ambion, Invitrogen) was amplified by PCR on
LightCycler ST300 (Roche Diagnostics, Tokyo, Japan) using
SYBR Green I and the primer sets described above. The ex-
pression levels of target genes were standardized against
the levels of G3PDH detected in the corresponding cDNA
samples. All assays were performed in triplicate.
Multiple sequence alignment analysis
We performed multiple sequence alignment analysis
using CLC Sequence Viewer 7 (CLC bio-Qiagen, Aarhus,
Denmark). We imported amino acid sequences of human
PLD1 [NCBI:NP_002653.1], PLD2 [NCBI:NP_002654.3],
PLD3 [NCBI:NP_036400.2], PLD4 [NCBI:NP_620145.2],
PLD5 [NCBI:NP_689879.2], and PLD6 [NCBI:NP_849158.2],
and PLD3 orthologs derived from Bos Taurus [NCBI:
NP_001071509.1], Mus musculus [NCBI:NP_035246.1],
Rattus norvegicus [NCBI:NP_001012167.1], Danio rerio
[NCBI:XP_003200538.1], Xenopus laevis [NCBI:NP_
001083260.1], Drosophila melanogaster [NCBI:NP_610093.1],
and Caenorhabditis elegans [NCBI:NP_504824.1].Genotyping analysis
Two variants of the human PLD3 gene, such as
rs145999145 comprised of p.Val232Met (p.V223M) cor-
responding to c.694G > A located in exon 7 and rs4819
comprised of p.Ala442Ala (p.A442A) corresponding to
c.1326G > A located in exon 11, were studied by direct
sequencing of PCR products amplified from brain cDNA
by using sense and antisense primer sets comprised of 5′-
cgcatggtggacatgcagaag-3′ and 5′-ggtgtctcttggttgtagcgg-3′
for rs145999145 and 5′-tgctctctctggctgccctgcgtg-3′ and
5′-tcagagcaggcggcaggcgttgcc-3′ for rs4819.
Coexpression database search
The Coexpression database (COXPRESdb) version 5.0
[22] is freeware of bioinformatics that contains the col-
lection of comprehensive information on gene coex-
pression retrieved from large sets of public microarray
data to estimate gene functions of 11 species, including
Homo sapiens, M. musculus, R. norvegicus, D. melano-
gaster, and C. elegans [23]. For human, COXPRESdb
includes coexpression data derived from 79,948 microar-
rays, whose raw data are extracted from ArrayExpress and
normalized by the robust multi-array average method.
COXPRESdb helps us to identify coexpression relation-
ships for a given gene with the probability evaluated by
the reliability score and to illustrate the interactive net-
work of the genes surrounding a focused gene on Cytos-
cape web. By searching on COXPRESdb, we identified the
set of genes coexpressed with PLD3, which potentially
contain candidates for PLD3 interactors.
Vector construction, transfection, and
immunoprecipitation
The full-length open reading frame of the human PLD3
gene or the human GRN gene, selected as a candidate for
PLD3 interactors, was amplified by PCR using PfuTurbo
DNA polymerase (Agilent Technologies, Palo Alto, CA,
USA) and the set of sense and antisense primers. Sub-
sequently, PCR products were cloned in the expression
vector named p3XFLAG-CMV7.1 (Sigma), pCMV-Myc
(Clontech, Mountain View, CA, USA), pDsRed-Express-
C1 (Clontech), or pZsGreen1-N1 (Clontech) to express a
fusion protein with an N-terminal Flag tag, Myc tag,
DsRed tag, or C-terminal ZsGreen tag, respectively. The
vectors were transfected in HEK293 cells, HeLa cells or
SK-N-SH cells using Lipofectamine 2000 reagent (Invitro-
gen) for transient expression. The M232 isoform of PLD3
was prepared from the cloned vector using QuickChange
Lightning Site-Directed Mutagenesis Kit (Agilent Tech-
nologies). After cotransfection of the vectors, the protein
extract was processed for immunoprecipitation with
mouse monoclonal anti-Flag M2 affinity gel (Sigma) or
rabbit polyclonal anti-Myc-conjugated agarose (Sigma),





















































Figure 1 Constitutive expression of PLD3 mRNA in human
neural cells. mRNA expression was studied by reverse transcription
(RT)-polymerase chain reaction in human tissues and cultured cells.
(a) PLD1, (b) PLD2, (c) PLD3, (d) PLD4, (e) PLD5, (f) PLD6, and (g)
glyceraldehyde-3-phosphate dehydrogenase (G3PDH). Lane 1, frontal
cortex of the human cerebrum (CBR) with inclusion of the RT step;
lane 2, CBR without inclusion of the RT step; lane 3, astrocytes (AS);
lane 4, neuronal progenitor (NP) cells; lane 5, NTera2 teratocarcinoma-
derived neurons (NTera2N); lane 6, SK-N-SH neuroblastoma; lane 7,
IMR-32 neuroblastoma; lane 8, U-373MG glioblastoma; lane 9, T98G
glioblastoma; lane 10, HMO6 immortalized microglia. cDNA was
amplified by PCR for 35 cycles, except for G3PDH that was amplified
for 28 cycles. PLD, phospholipase D.
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antibody (Sigma), respectively.
Western blot analysis
To prepare total protein extract, brain tissues and cultured
cells were homogenized in RIPA buffer (Sigma) supple-
mented with a cocktail of protease inhibitors (Sigma),
followed by centrifugation at 12,000 rpm for 10 minutes
at room temperature to harvest the supernatant. The
protein was separated on a 12% SDS-PAGE gel. After
gel electrophoresis, the protein was transferred onto
nitrocellulose membranes, followed by incubation at
room temperature overnight with the anti-PLD3 anti-
body HPA012800 or a rabbit monoclonal anti-PGRN
antibody (EPR3781; Abcam, Cambridge, UK). The mem-
brane was then incubated at room temperature for
30 minutes with horseradish peroxidase-conjugated
anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). The specific reaction was visualized by ex-
posing membranes to a chemiluminescent substrate
(Thermo Scientific). After the antibody was stripped by
incubating membranes at 50°C for 30 minutes in the
stripping buffer, composed of 62.5 mM Tris–HCl,
pH 6.7, 2% SDS and 100 mM 2-mercaptoethanol, it
was processed for relabeling with a goat polyclonal
anti-HSP60 antibody (sc-1052; Santa Cruz Biotechnology)
or a rabbit polyclonal anti-G3PDH antibody (GTX100118;
GeneTex, Irvine, CA, USA), serving as an internal control
of protein loading. The signal intensity of the major band
was quantified using ImageJ (National Institute of Health,
Bethesda, MD, USA). The expression levels of PLD3 were
standardized by the corresponding signal intensity of
HSP60 or G3PDH.
Statistical analysis
The statistical significant difference compared between
AD (n =7) and non-AD (n =14) groups was evaluated by
Student’s t test. P <0.05 by the two-tailed test was con-
sidered significant.
Results
Amino acid sequence homology of human PLD proteins
First, to characterize phylogenetic variation of PLD pro-
teins, we performed multiple sequence alignment analysis.
The amino acid sequence of the human PLD3 protein is
96%, 92%, 92%, 58%, 54%, 48%, and 41% identical to the
sequences of PLD3 orthologs derived from B. Taurus, M.
musculus, R. norvegicus, D. rerio, X. laevis, D. melanoga-
ster, and C. elegans, respectively (Additional file 2). All of
them contain two copies of the conserved HXKXXXXD/E
(HKD) motif, indicating the high level of conservation of
PLD3 through evolution. In contrast, the amino acid se-
quence of the human PLD3 protein showed only 5.7%,
8.5%, 42.5%, 33.9%, and 10.0% identity to the sequences ofthe human PLD1, PLD2, PLD4, PLD5, and PLD6 proteins,
all of which represent PLD3 paralogs (Additional file 3).
Thus, we identified PLD4 as the paralog most closely re-
lated to PLD3, although the amino acid sequence hom-
ology is fairly limited between both.
Constitutive expression of PLD3 mRNA in human neural
cells
Next, we studied mRNA expression of PLD3 paralogs in
human neural cell lines and tissues by RT-PCR. The
human cerebrum, astrocytes, neuronal progenitor cells,
NTera2 teratocarcinoma-derived neurons, SK-N-SH
neuroblastoma, IMR-32 neuroblastoma, U-373MG glio-
blastoma, T98 glioblastoma, and HMO6 immortalized
microglia constitutively expressed PLD1, PLD2, and PLD3
transcripts (Figure 1a,b,c, lanes 1, 3 to 10). In contrast,
more limited cell and tissue types expressed PLD4, PLD5,
and PLD6 transcripts (Figure 1d,e,f, lanes 1, 3 to 10).
G3PDH, a housekeeping gene serving as a positive
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(Figure 1g, lanes 1, 3 to 10), while no products were
amplified when the reverse transcription step was
omitted (Figure 1a to g, lane 2). We thus found that
PLD1, PLD2 and PLD3 are expressed constitutively in
a wide range of human neural cells.
Reduced expression of PLD3 mRNA and protein in
Alzheimer’s disease brains
Next, we studied PLD3 mRNA and protein expression
in frozen tissues of the frontal cortex, derived from four
patients that died from non-neurological causes, six
amyotrophic lateral sclerosis patients, four Parkinson’s
disease patients, and seven AD cases (Table 1). Before
starting this, we determined the genotype of rs145999145
and rs4819 of the human PLD3 gene in all samples.
The nonsynonymous single nucleotide polymorphism
rs145999145 comprised of p.V232M corresponding to
c.694G > A in exon 7 represents the most significant
AD risk-associated variant among several single nucleo-
tide polymorphisms on PLD3, on which the M232 isoform
confers a doubled risk for development of late-onset AD
[5]. However, in our series, all AD and non-AD cases
exhibited the V232 isoform (Table 1; Additional file 4).
The synonymous single nucleotide polymorphism rs4819
comprised of p.A442A corresponding to c.1326G >A in
exon 11 affects alternative splicing, leading to reduced ex-
pression of exon 11 containing transcripts [5]. In our
series, all AD and non-AD cases exhibited the common
allele c.1326G (Table 1). These results suggested that AD
risk-associated variants on rs145999145 and rs4819 are
extremely rare even in AD patients, consistent with the
genotyping data of the cohorts participating in the NHLBI
Exome Sequencing Project.
By qPCR, AD cases showed reduced PLD3 mRNA
levels, when compared with the levels in non-AD cases
at a marginal significance level (P =0.0499) (Figure 2a,b).
By western blot using HPA012800, whose specificity
was validated by immunoblot of recombinant PLD3
expressed in HEK293 cells (Additional file 1), AD cases
showed significantly reduced PLD3 protein levels, when
compared with the levels in non-AD cases following
standardization against HSP60 (P =0.0416) (Figure 2c,
d). However, this difference did not reach statistical sig-
nificance when PLD3 protein levels were standardized
against those of G3PDH (P =0.1644). Taken together, we
tentatively concluded that PLD3 expression is reduced
in AD brains but modestly at both mRNA and protein
levels.
Accumulation of PLD3 immunoreactivity in neuritic
plaques in Alzheimer’s disease brains
Next, by immunohistochemistry using HPA012800, we
studied the expression of PLD3 immunoreactivity in thefrontal cortex and the hippocampus of 10 AD cases and
13 non-AD cases, composed of four non-neurological
cause controls, four amyotrophic lateral sclerosis pa-
tients, three Parkinson’s disease patients, and two mul-
tiple system atrophy cases (Table 1). In all cases, nearly
all cortical neurons, hippocampal pyramidal neurons
and dentate gyrus granule cells expressed intense PLD3
immunoreactivity with the location in the cytoplasm by
forming fine granular structures, enriched in the soma
and in proximal neurites (Figure 3a,b,c,d). A subset of
pericytes surrounding capillaries also expressed intense
PLD3 immunoreactivity (Figure 4b). Notably, numerous
senile plaques containing swollen dystrophic neurites
expressed intense PLD3 immunoreactivity in the frontal
cortex of AD brains (Figure 4a,c,d). In contrast, PLD3-
labeled senile plaques were barely found in non-AD
brains (data not shown). PLD3 immunoreactivity on
neurons and senile plaques was completely abolished, when
the tissue sections were incubated with the HPA012800
antibody preabsorbed by a recombinant PLD3 fragment
spanning amino acid residues 93 to 218 (Additional file 5).
By double labeling, senile plaques reactive for PLD3
were decorated with Aβ immunoreactivity (Figure 5a).
In contrast, oligodendocytes located in the white matter
did not express PLD3 (Figure 4b). Furthermore, reactive
astrocytes and activated microglia accumulated in the
center of senile plaques and surrounding them did not
express PLD3 (Figure 5b,c). Senile plaques reactive for
PLD3 were often accompanied by loss of PLD3-positive
cortical neurons (Figure 4c). In the hippocampus of AD
brains, senile plaques containing swollen dystrophic neur-
ites expressed intense PLD3 immunoreactivity, often ac-
companied by loss of PLD3-positive pyramidal neurons
(Figure 6a,b,c). AT8-positive neurofibrillary tangles in the
hippocampal neurons were frequently decorated with
PLD3 immunoreactivity (Figure 5d), whereas the vacuoles
of granulovacuolar degeneration, which are most often
found in the hippocampal CA1 region of AD brains, were
devoid of PLD3 immunoreactivity (Figure 6d). We thus
found that PLD3 immunoreactivity is accumulated on
neuritic plaques in AD brains.
Molecular interaction of PLD3 with progranulin
Next, to investigate the role of PLD3 in AD pathology,
we attempted to identify a potential interactor for PLD3
by the bioinformatics approach. By searching the genes
coexpressed with PLD3 on COXPRESdb [23], we identi-
fied the human GRN gene encoding PGRN, whose muta-
tion is responsible for frontotemporal lobar degeneration
(FTLD) and neuronal ceroid lipofuscinosis [24], ranked as
the second most significant gene coexpressed with PLD3
(Additional file 6). The correlation coefficient of gene ex-
pression between PLD3 and PGRN exceeds 0.4, suggesting




Figure 3 PLD3 immunoreactivity in non-Alzheimer’s disease brains. PLD3 immunoreactivity was studied in non-Alzheimer’s disease brains by
immunohistochemistry. (a) Non-neurological control, the frontal cortex, neuronal cytoplasmic labeling. (b) Non-neurological control, the hippocampal CA1
region, neuronal cytoplasmic labeling. (c) Parkinson’s disease patient, the hippocampal CA1 region, neuronal cytoplasmic labeling. (d) Amyotrophic lateral









Figure 2 Reduced expression of PLD3 mRNA and protein in Alzheimer’s disease brains. (a), (b) PLD3 mRNA expression. mRNA expression
was studied by quantitative reverse transcription-polymerase chain reaction (qPCR) in human brain tissues derived from a reference of the human
frontal cortex (REF), four non-neurological controls (NC), six amyotrophic lateral sclerosis (ALS) patients, four Parkinson’s disease (PD) patients, and
seven Alzheimer’s disease (AD) cases. PLD3 expression levels were standardized against those of glyceraldehyde-3-phosphate dehydrogenase
(G3PDH), and the statistical significance in difference between AD and non-AD groups was evaluated by Student’s t test. *P =0.0499 (PLD3 vs.
G3PDH). (c), (d) PLD3 protein expression. Protein expression was studied by western blot in human brain tissues derived from four NC, six ALS
patients, four PD patients, and seven AD cases. PLD3 expression levels were standardized against those of HSP60 or G3PDH, and the statistical
significance in difference between AD and non-AD groups was evaluated by Student’s t test. *P =0.0416 (PLD3 vs. HSP60). PLD, phospholipase D.





Figure 4 PLD3 immunoreactivity in Alzheimer’s disease brains (I). PLD3 immunoreactivity was studied in Alzheimer’s disease brains by
immunohistochemistry. (a) to (d) Numerous senile plaques containing dystrophic neurites expressing intense PLD3 immunoreactivity in the
frontal cortex. Arrowheads in (d) represent swollen neurites in senile plaques. Arrow in (b) indicates pericyte cytoplasmic labeling in the white
matter. PLD, phospholipase D.
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variants serve as a risk factor for AD [25,26]. Thereafter,
we focused our attention on GRN (PGRN) as the most
promising candidate for PLD3 interactors in the present
study. The database search also showed that the set of
genes coexpressed with PLD3 constitute the molecular
network enriched with lysosomal proteins (Figure 7B). Bya b
c d
Figure 5 PLD3 immunoreactivity in Alzheimer’s disease brains (II). PLD
double-labeling immunohistochemistry. (a) Frontal cortex, PLD3 (brown), a
Frontal cortex, PLD3 (brown), GFAP (red), reactive astrocytes do not expres
do not express PLD3. (d) Hippocampal CA1 region, PLD3 (brown), AT8-tau
PLD, phospholipase D.coimmunoprecipitation experiments, we validated a direct
interaction between Myc-tagged PLD3 and Flag-tagged
PGRN (Figure 7C,a,b). Furthermore, we identified a partial
overlap of ZsGreen-tagged PLD3 and DsRed-tagged
PGRN in cytoplasmic granular structures of SK-N-SH
cells (Figure 7D,a to c). By double-labeling immunohis-
tochemistry, we identified coexpression of PLD3 and3 immunoreactivity was studied in Alzheimer’s disease brains by
myloid beta (Aβ; red), colocalization of PLD3 and Aβ (arrows). (b)
s PLD3. (c) Frontal cortex, PLD3 (brown), CD68 (red), activated microglia




Figure 6 PLD3 immunoreactivity in Alzheimer’s disease brains (III). PLD3 immunoreactivity was studied in Alzheimer’s disease brains by
immunohistochemistry. (a) to (d) Senile plaques containing dystrophic neurites expressing intense PLD3 immunoreactivity in the hippocampal
CA1 region. Arrowheads in (b) and (c) represent swollen neurites in senile plaques. Arrows in (d) indicate granulovaculoar degeneration in
hippocampal CA1 neurons. PLD, phospholipase D.
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Taken together, we found that PLD3 is coexpressed
and interacts with PGRN both in cultured cells in vitro
and in AD brains in vivo.
Finally, we studied biological effects of PLD3 on PGRN
protein expression in SK-N-SH cells. Transient overex-
pression of Flag-tagged PLD3, either V232 or M232, or
GFP as a negative control did not alter PGRN protein
levels (Figure S6a,b,c,d, lanes 1 to 4 in Additional file 7).
These results suggested that PLD3 is unlikely to act as a
direct regulator of PGRN protein expression.
Discussion
A recent whole-exome sequencing study showed that a
rare variant rs145999145 composed of p.V232M located
in exon 7 of the PLD3 gene confers a doubled risk for
late-onset AD [5]. However, the precise cellular location
and distribution of PLD3 in AD brains remain largely
unknown. We studied PLD3 expression patterns and
levels in a series of AD and control brains by qPCR,
western blot, immunohistochemistry, and bioinformatics
analysis. We found that the levels of PLD3 mRNA and
protein expression are reduced in AD brains but mod-
estly, consistent with the previous observations showing
that PLD3 mRNA levels are decreased in AD brains
based on the public microarray dataset numbered
GSE5281 [5]. PLD3 is expressed constitutively in human
neural cell lines, and cortical neurons, hippocampal pyr-
amidal and granular neurons, and vascular pericytes but
not in glial cells in human brains. We for the first timeshowed that PLD3 immunoreactivity is accumulated in
dystrophic neurites on senile plaques, most prominently
in AD brains, regardless of reduced levels of PLD3. We
assume that reduced expression of PLD3 is attributable to a
profound decrease in total populations of neurofilament-
positive neurons in AD brains, as reported recently [19].
By bioinformatics approach, we identified PRGN as
one of the most significant genes coexpressed with PLD3
on COXPRESdb, a comprehensive database of gene coex-
pression [23]. We found that PLD3 is actually coexpressed
and interacts with PGRN both in cultured cells in vitro
and in AD brains in vivo. A previous study showed that
PGRN acts as a chemotactic factor for microglia and
PGRN-treated microglia exhibit an enhanced capacity
to phagocytose Aβ1–42 [27]. Recently, we found that
senile plaques, neurofibrillary tangles, and the perivas-
cular neuropil express PGRN immunoreactivity in AD
brains [19]. Supporting this, PGRN expression is en-
hanced on dense core amyloid plaques in a transgenic
mouse model of AD [28]. Interestingly, PLD3 mRNA
expression is decreased in the brains of the patients
with GRN-mutated FTLD with ubiquitinated TAR
DNA-binding protein-43-positive inclusions [29]. These
observations suggest that PLD3, coexpressed with PRGN,
plays a key role in senile plaque formation and neurode-
generation in AD brains.
At present, the precise biological function of PLD3 re-
mains unknown in the human central nervous system.
We found that PLD3 orthologs are highly conserved





Figure 7 Coexpression and molecular interaction of PLD3 with progranulin. (A), (B) Coexpression of PLD3 and progranulin (PGRN). The
genes coexpressed with PLD3 were identified by database search on COXPRESdb [23] and are listed in Additional file 6. (A) Correlation coefficient
of gene expression between PLD3 (x axis indicates probe ID 201050_at) and PRGN (y axis indicates probe ID 216041_x_at) is 0.454. (B) Interactive
network of the set of genes coexpressed with PLD3 shows an enrichment of lysosomal proteins (nodes indicated in red). The interaction
between PLD3 and GRN is highlighted by a blue square. (C) Coimmunoprecipitation of PLD3 and PGRN. Myc-tagged PLD3 and Flag-tagged
PGRN were coexpressed in HEK293 cells. The protein extract was processed for (a) immunoprecipitation (IP) with anti-Flag antibody
followed by western blot (WB) with anti-Myc antibody or (b) IP with anti-Myc antibody followed by WB with anti-Flag antibody. Lane 1,
input control; lane 2, IP with the specific antibody; lane 3, IP with normal IgG. (D) Colocalization of PLD3 and PGRN in cultured cells.
ZsGreen-tagged PLD3 and DsRed-tagged PGRN were coexpressed in SK-N-SH cells. (a) PLD3, (b) PGRN, and (c) merge. (E) Colocalization of
PLD3 and PGRN in Alzheimer’s disease (AD) brains. The coexpression of PLD3 (brown) and PGRN (red) was studied in the frontal cortex of AD brains
by double-labeling immunohistochemistry. Arrows indicate the prominent accumulation of PLD3 and PGRN on neuritic plaques. Ab, antibody; PLD,
phospholipase D.
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ever, PLD3 but not PLD4 is expressed constitutively in
various human neural cell lines, suggesting a housekeep-
ing function of PLD3 required for the maintenance of vital
cellular processes. For example, PLD3 is identified as one
of irradiation-responsive genes in human lymphoblastoid
cells, serving as a genetic modifier for breast cancer
susceptibility genes BRCA1 and BRCA2 [30], suggesting
a role of PLD3 in DNA damage response.We found that the set of genes coexpressed with PLD3
constitute a lysosomal protein network. In contrast, previ-
ous studies showed that PLD3 is a type 2 transmembrane
glycoprotein primarily located in ER [18,31]. PLD3 expres-
sion levels are elevated in mouse C2C12 cells following
ER stress [31]. PGRN is accumulated in the ER and the
Golgi complex in mouse cortical neurons and microglia
[32]. These observations suggest that PLD3 interacts with
PRGN in the ER compartment in human neurons.
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membrane protein 2 (LAMP2), an endosome/lysosome
marker in HeLa cells [33]. Sortilin, serving as a cell-surface
receptor for PGRN, regulates trafficking and targeting
of PGRN to lysosomes [34]. Therefore, an alternative
possibility exists that PLD3 cooperates physiologically
with PRGN in the lysosomal compartment in human
neurons. Starvation stress transports PLD1 located prin-
cipally in late endosomes and the Golgi complex to the
outer membrane of microtubule-associated protein 1
light chain 3-positive amphisome, an autophagic vacuole
formed by fusion of an autophagosome and an endosome,
suggesting a pivotal role for PLD1 in the regulation of au-
tophagy [35]. These observations suggest that subcellular
location of PLD enzymes is changeable, depending on cell
types and cellular microenvironments in the context of
interacting proteins. We could therefore propose a
working hypothesis that PLD3 transported from ER to
endosome/lysosome/autophagosome compartments might
play a pivotal role in regulation of autophagy.
The database search of rs145999145 composed of p.
V232M located in exon 7 of the PLD3 gene on the
Polymorphism Phenotyping v2 (Polyphen-2) program
[36] indicates that this variant produces a potentially
deleterious effect on protein function [5]. By PCR-based
direct sequencing, we could not find the AD risk-
associated variant M232 in any AD and non-AD cases
examined. However, even a subtle decrease in PLD3
expression and function could cause production of
greater amounts of amyloidogenic species of Aβ, in
view of the evidence that PLD3 acts as a negative regula-
tor of APP processing [5]. Since PLD3 is coexpressed with
PGRN, the possibility exists that PLD3 acts as a positive
regulator of PRGN production – as transmembrane pro-
tein 106B (TMEM106B), one of the risk genes for FTLD
with ubiquitinated TAR DNA-binding protein-43-positive
inclusions, does [37]. With the respect to the GRN gene, a
partial loss of function causes FTLD with ubiquitinated
TAR DNA-binding protein-43-positive inclusions, while
the complete loss of function develops neuronal ceroid
lipofuscinosis [24]. We therefore studied direct effects of
PLD3 on PGRN protein expression in SK-N-SH cells.
However, we found that overexpression of PLD3, either
the V232 or M232 isoform, does not affect PGRN protein
expression, suggesting that PLD3 does not act as a direct
regulator of PGRN protein production.
Conclusions
The levels of PLD3 mRNA and protein expression were re-
duced in AD brains, consistent with previous observations
[5]. Notably, we for the first time identified an intense accu-
mulation of PLD3 on neuritic plaques coexpressed with
PGRN in AD brains, suggesting the possibility that PLD3
plays a key role in the pathological processes of AD.Additional files
Additional file 1: Figure S1 showing characterization of anti-PLD3
antibody. The full-length open reading frame of the human PLD3 gene
cloned in the vector expressing a fusion protein with an N-terminal Flag
tag was transiently expressed in HeLa cells. The protein extract was
processed for western blot. (a) PLD3, the HPA012800 antibody, (b) Flag,
and (c) HSP60, an internal control for protein loading. Lanes 1 and 2
represent the protein extract of (1) non-transfected cells and (2) cells
expressing PLD3. The Flag-tagged PLD3 protein is expressed as three
distinct bands possibly derived from differential glycosylation [18].
Additional file 2: Figure S2 showing multiple sequence alignment
of PLD3 orthologs. Multiple sequence alignment analysis was
performed by importing the corresponding amino acid sequences into
CLC Sequence Viewer 7. The sequences are derived from the PLD3
protein of Homo sapiens, Bos Taurus, Mus musculus, Rattus norvegicus,
Danio rerio, Xenopus laevis, Drosophila melanogaster, and Caenorhabditis
elegans. The conserved HXKXXXXD/E (HKD) motifs are highlighted by the
red line.
Additional file 3: Figure S3 showing multiple sequence alignment
of PLD3 paralogs. Multiple sequence alignment analysis was performed
by importing the corresponding amino acid sequences into CLC
Sequence Viewer 7. The sequences are derived from the human PLD1,
PLD2, PLD3, PLD4, PLD5, and PLD6 proteins. The conserved HXKXXXXD/E
(HKD) motifs are highlighted by the red line.
Additional file 4: Figure S4 showing genotyping analysis of p.
Val232Met. The genotype of rs145999145 (c.694G>A, p.V232M) located
in exon 7 of the human PLD3 gene was studied by direct sequencing of
PCR products amplified from brain cDNA. (a) to (d) indicate V232/V232
homozygote (underline) of representative cases of (a) non-neurological
controls (NC), (b) amyotrophic lateral sclerosis (ALS) patients, (c) Parkin-
son’s disease (PD) patients, and (d) AD cases.
Additional file 5: Figure S5 showing validation of the specificity of
anti-PLD3 antibody by immunoabsorption. PLD3 immunoreactivity
was studied in the frontal cortex of AD brains by immunohistochemistry.
(a), (b) Immunolabeling with (a) the HPA012800 antibody and (b) the
antibody preabsorbed by a recombinant PLD3 fragment spanning amino
acid residues 93 to 218.
Additional file 6: Table S1 presenting the top 20 significant genes
coexpressed with PLD3 on COXPRESdb.
Additional file 7: Figure S6 showing PLD3 overexpression did not
alter the levels of PRGN protein expression in SK-N-SH cells.
Flag-tagged GFP or PLD3, either V232 or M232, was transiently expressed
for 48 hours in SK-N-SH cells. The protein extract was then processed for
western blot. (a) PLD3, (b) Flag, (c) PGRN, and (d) Hsp60, as an internal
control for protein loading. Lanes 1 to 4 represent the protein extract of
(1) nontransfected cells, and the cells expressing (2) GFP as a negative
control, (3) PLD3-V232, and (4) PLD3-M232.
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